Genekam

Genekam Biotechnology AG, founded in 1999, is a German company specializing in the development and manufacturing of diagnostic and therapeutic solutions, particularly focusing on virology, stem cells, and immunology. Headquartered in Duisburg, Germany, Genekam offers a diverse portfolio of over 700 products, including ready-to-use PCR kits for detecting pathogens such as Ebola, HIV, CMV, and various influenza viruses. Many of these kits are CE-IVD marked, indicating their approval for clinical use.

In addition to diagnostics, Genekam is actively engaged in developing therapeutic molecules. Notably, the company has pioneered a therapeutic molecule candidate targeting Zika virus infections, aiming to address complications like microcephaly in newborns.

Genekam is also advancing research in nanomedicine, creating innovative solutions to enhance virus detection and treatment. Their commitment to quality and innovation has established them as a trusted partner in the biotechnology sector.